非酒精性脂肪性肝炎（NASH）：我们现在处于什么阶段，又将走向何方？
Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?
作者信息
Day C P
机构信息
Centre for Liver Research, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
出版信息
Gut. 2002 May;50(5):585-8. doi: 10.1136/gut.50.5.585.
Abstract
Although non-alcoholic steatohepatitis (NASH) was considered relatively uncommon prior to the middle of the last decade, over the past three years there has been an explosion of studies on various aspects of NASH with one study reporting that after hepatitis C, NASH was the most common diagnosis in patients presenting largely with persistent abnormalities of liver function tests. The field of NASH has come a long way in a relatively short space of time. This article considers advances in knowledge that have arisen as a result of these studies and highlights areas for further work.
摘要
尽管在过去十年中叶之前，非酒精性脂肪性肝炎（NASH）被认为相对不常见，但在过去三年里，关于NASH各个方面的研究呈爆发式增长。有一项研究报告称，除丙型肝炎外，NASH是肝功能检查持续异常的患者中最常见的诊断结果。在相对较短的时间内，NASH领域已经取得了长足的进展。本文探讨了这些研究带来的知识进步，并强调了有待进一步开展工作的领域。
相似文献
1
Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?非酒精性脂肪性肝炎（NASH）：我们现在处于什么阶段，又将走向何方？
Gut. 2002 May;50(5):585-8. doi: 10.1136/gut.50.5.585.
2
Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?非酒精性脂肪性肝炎：它是什么，以及为何在亚太地区至关重要？
J Gastroenterol Hepatol. 2003 Feb;18(2):124-38. doi: 10.1046/j.1440-1746.2003.02989.x.
3
Non-alcoholic steatohepatitis: an overview.非酒精性脂肪性肝炎：概述
J Formos Med Assoc. 2009 Jan;108(1):4-12. doi: 10.1016/S0929-6646(09)60026-7.
4
Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?脂肪肝与非酒精性脂肪性肝炎。我们目前的状况如何，又将走向何方？
Dig Dis. 1999;17(2):80-9. doi: 10.1159/000016909.
5
Non-alcoholic steatohepatitis in children.儿童非酒精性脂肪性肝炎
Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x.
6
[Non-alcoholic liver disease (NASH)].[非酒精性肝病（NASH）]
Praxis (Bern 1994). 2006 Aug 23;95(34):1267-9. doi: 10.1024/0369-8394.95.34.1267.
7
8
Nonalcoholic fatty liver disease: a challenge for pediatricians.非酒精性脂肪性肝病：儿科医生面临的挑战。
Int J Obes (Lond). 2010 Oct;34(10):1451-67. doi: 10.1038/ijo.2010.185. Epub 2010 Sep 14.
9
Non-alcoholic fatty liver disease: an overview.
J Gastroenterol Hepatol. 2002 Nov;17(11):1136-43. doi: 10.1046/j.1440-1746.2002.02881.x.
10
[Non-alcoholic fatty liver disease--new view].[非酒精性脂肪性肝病——新视角]
Pol Merkur Lekarski. 2008 Jun;24(144):568-71.
引用本文的文献
1
Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment.非酒精性脂肪性肝炎：对风险因素、症状及治疗的全面更新综述
Heliyon. 2024 Mar 25;10(7):e28468. doi: 10.1016/j.heliyon.2024.e28468. eCollection 2024 Apr 15.
2
Dihydroartemisinin ameliorates the liver steatosis in metabolic associated fatty liver disease mice by attenuating the inflammation and oxidative stress and promoting autophagy.双氢青蒿素通过减轻炎症和氧化应激以及促进自噬来改善代谢相关脂肪性肝病小鼠的肝脂肪变性。
Acta Cir Bras. 2023 Oct 13;38:e385023. doi: 10.1590/acb385023. eCollection 2023.
3
Prevalence of non-alcoholic fatty liver disease in patients with nephrotic syndrome: A population-based study.肾病综合征患者中非酒精性脂肪性肝病的患病率：一项基于人群的研究。
World J Hepatol. 2023 Feb 27;15(2):265-273. doi: 10.4254/wjh.v15.i2.265.
4
Mitochondrial Peroxiredoxin III Protects against Non-Alcoholic Fatty Liver Disease Caused by a Methionine-Choline Deficient Diet.线粒体过氧化物酶体增殖物激活受体III可预防由蛋氨酸-胆碱缺乏饮食引起的非酒精性脂肪性肝病。
Antioxidants (Basel). 2022 Dec 21;12(1):9. doi: 10.3390/antiox12010009.
5
Pharmacological Mechanism of Ganlu Powder in the Treatment of NASH Based on Network Pharmacology and Molecular Docking.基于网络药理学和分子对接探讨肝露散治疗 NASH 的作用机制。
Dis Markers. 2022 Jun 29;2022:7251450. doi: 10.1155/2022/7251450. eCollection 2022.
6
A Decade of Mighty Lipophagy: What We Know and What Facts We Need to Know?一个强大的脂噬十年：我们知道什么，我们需要知道什么事实？
Oxid Med Cell Longev. 2021 Nov 5;2021:5539161. doi: 10.1155/2021/5539161. eCollection 2021.
7
Zinc as a Drug for Wilson's Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury.锌作为治疗 Wilson 病、非酒精性肝病和 COVID-19 相关肝损伤的药物。
Molecules. 2021 Oct 31;26(21):6614. doi: 10.3390/molecules26216614.
8
Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.血清锌水平与非酒精性脂肪性肝病患者的肝纤维化。
PLoS One. 2020 Oct 23;15(10):e0240195. doi: 10.1371/journal.pone.0240195. eCollection 2020.
9
Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.非酒精性脂肪性肝病的自然史：一项配对肝活检研究
J Clin Exp Hepatol. 2020 May-Jun;10(3):245-254. doi: 10.1016/j.jceh.2019.07.002. Epub 2019 Jul 15.
10
Hepatoprotective Effect of Cranberry Nutraceutical Extract in Non-alcoholic Fatty Liver Model in Rats: Impact on Insulin Resistance and Nrf-2 Expression.蔓越莓营养提取物对大鼠非酒精性脂肪肝模型的肝保护作用：对胰岛素抵抗和Nrf-2表达的影响
Front Pharmacol. 2020 Mar 18;11:218. doi: 10.3389/fphar.2020.00218. eCollection 2020.
本文引用的文献
1
Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology.在缺乏诊断性血清学检查的情况下，为调查肝功能检查异常而进行肝活检的结果。
J Hepatol. 2001 Aug;35(2):195-9. doi: 10.1016/s0168-8278(01)00094-0.
2
Metformin in non-alcoholic steatohepatitis.二甲双胍用于非酒精性脂肪性肝炎
Lancet. 2001 Sep 15;358(9285):893-4. doi: 10.1016/s0140-6736(01)06042-1.
3
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.非酒精性脂肪性肝病：代谢综合征的一个特征。
Diabetes. 2001 Aug;50(8):1844-50. doi: 10.2337/diabetes.50.8.1844.
4
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.非酒精性脂肪性肝病：重度肥胖患者中非酒精性脂肪性肝炎和肝纤维化的预测因素
Gastroenterology. 2001 Jul;121(1):91-100. doi: 10.1053/gast.2001.25540.
5
Treatment of nonalcoholic fatty liver: present and emerging therapies.非酒精性脂肪性肝病的治疗：当前及新兴疗法
Semin Liver Dis. 2001;21(1):81-8. doi: 10.1055/s-2001-12931.
6
Mitochondria in steatohepatitis.
Semin Liver Dis. 2001;21(1):57-69. doi: 10.1055/s-2001-12929.
7
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.非酒精性脂肪性肝炎：胰岛素抵抗与线粒体异常的关联
Gastroenterology. 2001 Apr;120(5):1183-92. doi: 10.1053/gast.2001.23256.
8
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.噻唑烷二酮类药物曲格列酮治疗非酒精性脂肪性肝炎的一项初步研究。
Am J Gastroenterol. 2001 Feb;96(2):519-25. doi: 10.1111/j.1572-0241.2001.03553.x.
9
Prevalence of overweight and obese children between 1989 and 1998: population based series of cross sectional studies.1989年至1998年间超重和肥胖儿童的患病率：基于人群的系列横断面研究
BMJ. 2001 Feb 10;322(7282):326-8. doi: 10.1136/bmj.322.7282.326.
10
Zotero 插件